Earnings History Data for AcelRx Pharmaceuticals, Inc. (ACRX) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

AcelRx Pharmaceuticals, Inc.

AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of pain. The Company product candidates comprises: ARX-01 or the Sufentanil NanoTab PCA System; ARX-02 or the Sufentanil NanoTab BTP Management System; and ARX-03 or the Sufentanil/Triazolam NanoTab which are in their development stage. Its product ARX-01 is focused on acute post-operative pain, ARX-02 is focused on the treatment of cancer breakthrough pain and ARX-03 is focused on providing mild sedation, anxiety reduction, and pain relief to patients undergoing painful procedures in a physician's office. AcelRx Pharmaceuticals, Inc. is headquartered in Redwood City, California.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
14-11-2022	AH	4:00 PM ET (Nov 14)	ACRX	AcelRx Pharmaceuticals, Inc.	15.10	-0.94	-1.20	-1.40	AcelRx Pharmaceuticals GAAP EPS of -$0.94 beats by $0.26, revenue of $0.51M misses by $0.12M [11/14/2022 4:02 PM]	2.50	0.07 (2.88%)	2.23	-0.20 (-8.23%)	1.76 - 16.30	336,544	150,000	628
AcelRx Pharmaceuticals GAAP EPS of -$0.94 beats by $0.26, revenue of $0.51M misses by $0.12M [11/14/2022 4:02 PM] AcelRx Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update [Nov-14-22 04:01PM] AcelRx Pharmaceuticals (ACRX) Reports Q3 Loss, Misses Revenue Estimates [Nov-14-22 05:15PM]
11-08-2022	AH	4:00 PM ET (Aug 11)	ACRX	AcelRx Pharmaceuticals, Inc.	34.48	-0.06	-0.06	-0.08	AcelRx PharmaceuticalsEPS of $0.48, revenue of $0.57M beats by $0.02M [8/11/2022 4:02 PM]	0.2740	-0.04 (-12.35%)	0.26	-0.05 (-16.51%)	0.16 - 1.22	4,129,012	5,690,000	1,417,436
AcelRx PharmaceuticalsEPS of $0.48, revenue of $0.57M beats by $0.02M [8/11/2022 4:02 PM] AcelRx Pharma stock falls ~17% premarket after Q2 results, large runup in shares [8/12/2022 9:28 AM] AcelRx Pharmaceuticals Announces Abstract Acceptance for Podium Presentation at the ANESTHESIOLOGY® 2022 Annual Meeting [Aug-10-22 08:30AM] AcelRx Pharmaceuticals Announces Abstract Acceptance for Podium Presentation at Plastic Surgery: The Meeting 2022 [Aug-11-22 08:30AM] AcelRx Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update [Aug-11-22 04:01PM] AcelRx Pharmaceuticals (ACRX) Reports Q2 Loss, Misses Revenue Estimates [Aug-11-22 05:35PM]
16-05-2022	PM	6:00 AM ET (May 16)	ACRX	AcelRx Pharmaceuticals, Inc.	26.24	-0.06	-0.06	-0.08	AcelRx Pharmaceuticals GAAP EPS of -$0.06 in-line, revenue of $0.44M misses by $0.11M [5/16/2022 7:33 AM]	0.2108	0.0 (0.43%)	0.19	-0.02 (-9.00%)	0.16 - 1.67	638,573	1,170,000	22,274
AcelRx Pharmaceuticals GAAP EPS of -$0.06 in-line, revenue of $0.44M misses by $0.11M [5/16/2022 7:33 AM] AcelRx Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update [May-16-22 07:30AM] AcelRx Pharmaceuticals (ACRX) Reports Q1 Loss, Lags Revenue Estimates [May-16-22 08:45AM]
10-03-2022	AH	After the close (Mar 10)	ACRX	AcelRx Pharmaceuticals, Inc.	51.77	-0.06	-0.06	-0.10	AcelRx Pharmaceuticals GAAP EPS of -$0.06 beats by $0.01, revenue of $0.2M misses by $1.65M [3/10/2022 4:08 PM]	0.3458	-0.09 (-19.92%)	0.40	-0.03 (-7.60%)	0.32 - 2.30	2,838,150	760,000	70,706
AcelRx Pharmaceuticals GAAP EPS of -$0.06 beats by $0.01, revenue of $0.2M misses by $1.65M [3/10/2022 4:08 PM] AcelRx stock falls 18% following Q4 results [3/11/2022 10:38 AM] AcelRx Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results [Mar-10-22 04:01PM] AcelRx Pharmaceuticals (ACRX) Reports Q4 Loss, Misses Revenue Estimates [Mar-10-22 05:15PM]
15-11-2021	PM	7:35 AM ET (Nov 15)	ACRX	AcelRx Pharmaceuticals, Inc.	94.94	-0.07	-0.07	-0.10	AcelRx Pharmaceuticals EPS in-line, misses on revenue [11/15/2021 6:02 AM]	0.7436	-0.05 (-6.39%)	0.78	-0.01 (-1.81%)	0.73 - 2.94	2,445,528	850,000	211,188
AcelRx Pharmaceuticals EPS in-line, misses on revenue [11/15/2021 6:02 AM] AcelRx Pharma to acquire Lowell Therapeutics [11/15/2021 6:12 AM] AcelRx launches ~$14M securities offering [11/15/2021 9:59 AM] AcelRx Pharmaceuticals to Acquire Lowell Therapeutics and Reports Third Quarter 2021 Financial Results [Nov-15-21 06:00AM] AcelRx Announces $14 Million Registered Direct Common Stock and Warrant Offering [Nov-15-21 06:45AM]
16-08-2021	AH	4:00 PM ET (Aug 16)	ACRX	AcelRx Pharmaceuticals, Inc.	147.69	-0.08	-0.08	-0.08	AcelRx Pharmaceuticals EPS in-line, misses on revenue [8/16/2021 4:02 PM]	0.9199	-0.20 (-17.87%)	1.09	-0.03 (-2.68%)	0.75 - 2.94	8,192,387	1,060,000	302,301
AcelRx Pharmaceuticals EPS in-line, misses on revenue [8/16/2021 4:02 PM] Virpax Pharmaceuticals, Sesen Bio leads healthcare gainers; Qualigen Therapeutics, Sema4 among major losers [8/17/2021 11:03 AM] AcelRx Pharmaceuticals Reports Second Quarter 2021 Financial Results [Aug-16-21 04:01PM] AcelRx Pharmaceuticals (ACRX) Reports Q2 Loss, Lags Revenue Estimates [Aug-16-21 05:25PM]
17-05-2021	AH	4:00 PM ET (May 17)	ACRX	AcelRx Pharmaceuticals, Inc.	135.78	-0.08	-0.08	-0.20	AcelRx Pharmaceuticals EPS in-line, misses on revenue [5/17/2021 4:03 PM]	1.29	0.12 (9.75%)	1.17	-0.01 (-0.85%)	1.01 - 2.94	6,319,676	1,680,000	62,615
AcelRx Pharmaceuticals EPS in-line, misses on revenue [5/17/2021 4:03 PM] AcelRx shares fall on Q1 topline miss [5/17/2021 4:36 PM] AcelRx Pharmaceuticals, Inc. to Host Earnings Call [May-17-21 02:45PM] AcelRx Pharmaceuticals Reports First Quarter 2021 Financial Results [May-17-21 04:01PM]
15-03-2021	AH	4:05 PM ET (Mar 15)	ACRX	AcelRx Pharmaceuticals, Inc.	198.03	-0.10	-0.12	-0.18	AcelRx Pharmaceuticals EPS in-line, misses on revenue [3/15/2021 4:05 PM]	1.84	-0.34 (-15.37%)	1.95	-0.23 (-10.55%)	0.70 - 2.94	6,240,940	3,746,253	271,444
AcelRx Pharmaceuticals EPS in-line, misses on revenue [3/15/2021 4:05 PM] AcelRx shares fall after Q4 results, FY forecast [3/15/2021 4:30 PM] SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AcelRx Pharmaceuticals, Inc. (ACRX) [Mar-12-21 05:45AM] AcelRx Pharmaceuticals, Inc. to Host Earnings Call [Mar-15-21 02:30PM] AcelRx Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results [Mar-15-21 04:01PM] AcelRx Pharmaceuticals (ACRX) Reports Q4 Loss, Lags Revenue Estimates [Mar-15-21 05:15PM] AcelRx Pharmaceuticals: Q4 Earnings Insights [Mar-15-21 04:54PM]
05-11-2020	AH	4:00 PM ET (Nov 5)	ACRX	AcelRx Pharmaceuticals, Inc.	164.39	-0.10	-0.07	-0.16	AcelRx Pharmaceuticals EPS misses by $0.02, misses on revenue [11/5/2020 4:16 PM]	1.45	-0.42 (-22.46%)	1.56	-0.31 (-16.58%)	0.70 - 2.50	3,654,677	1,107,109	83,313

10-08-2020	AH	4:00 PM ET (Aug 10)	ACRX	AcelRx Pharmaceuticals, Inc.	94.49	-0.08	-0.14	-0.16	AcelRx Pharmaceuticals EPS beats by $0.06, beats on revenue [8/10/2020 4:05 PM]	1.27	-0.10 (-7.61%)	1.30	-0.08 (-5.80%)	0.70 - 2.80	1,004,660	1,201,452	100,318